A summary of the drug's efficacy in clinical studies.
In postmenopausal women with osteoporosis, EVISTA significantly increased bone mineral density and reduced the incidence of vertebral fractures. For invasive breast cancer risk reduction, clinical trials demonstrated significant reductions in incidence, primarily of estrogen receptor-positive tumors, in postmenopausal women with osteoporosis or those at high risk. It does not provide cardiovascular benefit.

